Trial Profile
A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 15 Apr 2019
Price :
$35
*
At a glance
- Drugs Rosuvastatin/telmisartan (Primary)
- Indications Hypercholesterolaemia; Hypertension
- Focus Therapeutic Use
- Sponsors Yuhan
- 10 Apr 2019 Status changed from recruiting to discontinued.
- 30 May 2017 Planned End Date changed from 1 Oct 2017 to 1 Jul 2018.
- 30 May 2017 Planned primary completion date changed from 1 Oct 2017 to 1 May 2018.